BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Biotech Bay

  Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader

  Nurix Therapeutics, Inc. announced the publication of a manuscript in the journal Science titled: “Kinase Impaired BTK Mutations Are Susceptible to Clinical Stage BTK and IKZF1/3 Degrader NX-2127”.

  February 1, 2024

   · 

  8 min read
• Biotech Bay

  Revolution Medicines to Participate in Upcoming Investor Conferences - February 01, 2024

  Revolution Medicines, Inc. announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and the TD Cowen 44th Annual Health Care Conference.

  February 1, 2024

   · 

  1 min read
• Business

  AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

  Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024, after the close of the U.S. financial markets.

  February 1, 2024

   · 

  2 min read
• Pharm Country

  Palatin Announces Closing of $10 Million Registered Direct Offering

  Palatin Technologies, Inc. announced the closing of its previously announced registered direct offering of 1,831,503 shares of its common stock, at a purchase price of $5.46 per share of common stock.

  February 1, 2024

   · 

  4 min read
• Genetown

  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2024

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 26,850 restricted stock units to seven newly-hired employees.

  February 1, 2024

   · 

  2 min read
• Business

  Hologic Announces Financial Results for First Quarter of Fiscal 2024

  Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 30, 2023.

  February 1, 2024

   · 

  29 min read
• Business

  Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call

  Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 15, 2024.

  February 1, 2024

   · 

  2 min read
• Business

  AVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Results

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) today announced that it will report its fourth quarter and full year 2023 financial results after the close of the U.S. financial markets on Thursday, February 22, 2024.

  February 1, 2024

   · 

  2 min read
• Business

  Penumbra, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 22, 2024

  Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2023 after market close on Thursday, February 22, 2024 at 4:30 PM Eastern Time.

  February 1, 2024

   · 

  1 min read
• Business

  Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results

  Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2023 financial results will be released on Thursday, February 15, 2024 after the market closes.

  February 1, 2024

   · 

  1 min read